RenovoRx Inc. (RNXT)
RNXT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1574094/000119312526131928/0001193125-26-131928-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | RNXT on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001574094 |
| SEC industry code | Surgical & Medical Instruments & Apparatus |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $1.1M |
| Net income | -$11.2M |
| Operating income | -$12.5M |
| Net margin | -994.5% |
| Operating margin | -1114.0% |
| Revenue growth | +2511.6% |
| Cash | $7.0M |
| Total assets | $8.1M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 41.0× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $10.4M cash; operating cash flow -$3.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | 48,250,592 (2026-10-30); 36,649,916 a year earlier; 10,693,580 three years earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-04-16 |
| Exchange deficiency notices, 12 months | 2 (8-K item 3.01) | 8-K 2026-07-02 |
| Auditor | Frank, Rimerman & Co. LLP, San Francisco, California, United States | PCAOB Form AP 2026-04-02 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $84K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $1.1M | -$3.6M | -$2.5M | $10.4M | No debt tags | $2.8M | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $909K | -$2.9M | -$2.9M | $9.5M | No debt tags | $2.0M | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | $563K | -$3.5M | -$3.7M | $12.4M | No debt tags | $1.5M | 10-Q 2026-05-14 |
| Q4 2025 2025-12-31 | $238K | -$2.9M | -$3.0M | $7.0M | No debt tags | $1.1M | 10-K 2026-03-30 |
| Q3 2025 2025-09-30 | $266K | -$2.9M | -$2.3M | $10.0M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $422K | -$2.9M | -$2.3M | $12.3M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | $197K | -$2.4M | -$3.4M | $14.6M | No debt tags | Needs four quarters | 10-Q 2026-05-14 |
| Q4 2024 2024-12-31 | Not filed | -$2.9M | -$2.4M | $7.2M | No debt tags | $43K | 10-K 2026-03-30 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-04-27 |
| Latest annual report | 10-K/A | 2026-05-15 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEF 14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 293 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -8.0% |
| 1 month | -9.6% |
| 3 months | -17.5% |
| Year to date | +23.8% |
| 1 year | +6.8% |
| From 52-week high | -58.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ANVS | Annovis Bio Inc. | $0.7500 | -19.02% | $46.5M |
| MIST | Milestone Pharmaceuticals Inc. Common Shares | $0.3650 | -29.81% | $45.4M |
| ATNM | Actinium Pharmaceuticals Inc. (Delaware) | $1.49 | -9.15% | $46.8M |
| NMAD | Nomad Power Solutions Inc. | $2.80 | +19.15% | $45.1M |
| TLPH | Talphera Inc. | $0.8609 | -4.98% | $44.7M |
| HYFT | MindWalk Holdings Corp. | $0.9378 | -8.95% | $44.6M |
| ONCY | Oncolytics Biotech Inc. | $0.3399 | -8.14% | $44.6M |
| HOWL | Werewolf Therapeutics Inc. | $0.9908 | +1.07% | $48.2M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier